Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) CFO Edward H. Myles sold 142,292 shares of Scholar Rock stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $35.62, for a total value of $5,068,441.04. Following the sale, the chief financial officer now directly owns 111,345 shares in the company, valued at $3,966,108.90. The trade was a 56.10 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Scholar Rock Stock Down 3.5 %
SRRK opened at $34.55 on Friday. Scholar Rock Holding Co. has a twelve month low of $6.76 and a twelve month high of $46.98. The firm has a market cap of $3.27 billion, a price-to-earnings ratio of -14.70 and a beta of 0.59. The firm’s 50-day simple moving average is $39.87 and its 200-day simple moving average is $30.99. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88.
Institutional Trading of Scholar Rock
Several large investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its holdings in shares of Scholar Rock by 51.8% in the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock worth $34,000 after acquiring an additional 269 shares in the last quarter. JPMorgan Chase & Co. raised its position in Scholar Rock by 1.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company’s stock valued at $310,000 after purchasing an additional 379 shares during the last quarter. Amalgamated Bank boosted its stake in Scholar Rock by 30.6% in the fourth quarter. Amalgamated Bank now owns 2,643 shares of the company’s stock worth $114,000 after purchasing an additional 620 shares in the last quarter. Global Retirement Partners LLC grew its holdings in shares of Scholar Rock by 584.7% during the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock worth $39,000 after purchasing an additional 766 shares during the last quarter. Finally, Nisa Investment Advisors LLC increased its stake in shares of Scholar Rock by 1,321.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock valued at $48,000 after buying an additional 1,031 shares in the last quarter. 91.08% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
View Our Latest Analysis on SRRK
Scholar Rock Company Profile
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
Featured Stories
- Five stocks we like better than Scholar Rock
- What Makes a Stock a Good Dividend Stock?
- 3 Undervalued Stocks You Can Buy at a Discount Now
- How to Choose Top Rated Stocks
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- What is a SEC Filing?
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.